# ClinicalTrials.gov record NCT03841058

> PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03841058-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03841058-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03841058-abaloparatide-v1.json
- Content SHA-256: `5612b7b1105ffa5bef9e8eb8d4857fff29b8421cb1e7a463397cbc27cefd4b4f`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03841058 ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`](#source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc))

## Sources

<a id="source-ctg-observation-nct03841058-2026-04-28-878f8bf410cc"></a>
- **ClinicalTrials.gov record NCT03841058 · retained source version 2026-04-28:878f8bf410cc1465657beba96cda5f8c11b3e52203dfd76026a6b7cc972c0d78** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03841058) (`ctg-observation-nct03841058-2026-04-28-878f8bf410cc`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03841058." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03841058-abaloparatide-v1.json SHA-256: 5612b7b1105ffa5bef9e8eb8d4857fff29b8421cb1e7a463397cbc27cefd4b4f.